Short-term Presurgical Study to Assess Molecular Predictors of Lapatinib's Effects in Primary Breast Cancer

NCT00299286 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

121

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: Lapatinib
DRUG: Lapatinib-Placebo

Sponsor

Institute of Cancer Research, United Kingdom

Collaborators

[object Object]